Live Demo · Prior-Art-Search Agent

Agent Run on EP 2 305 838 B1

Same agent your design pilot would use — run on a real, well-known patent. Espacenet + Google Patents search, LLM relevance scoring, structured novelty report.

Demo run on 2026-06-19. Results cached. Live agent available to design partners.
Prior Art Search Demo OA Response — USPTO §103 OA Response — EPO Art. 56 🔬 Prosecution Loop Case Study
Patent
EP 2 305 838 B1 — CRISPR-Cas Systems and Methods for Altering Expression of Gene Products
The Broad Institute / MIT (Zhang et al.)
Input
Invention Brief
Technology field: Genome editing, CRISPR-Cas systems, molecular biology
A method for editing the genome of a eukaryotic cell using a CRISPR-Cas9 system comprising: (1) a guide RNA (gRNA) engineered to include a spacer sequence complementary to a target DNA sequence within the eukaryotic cell's genome; (2) a Cas9 endonuclease capable of forming a complex with the gRNA and introducing a double-strand break at the target DNA sequence; and (3) optionally, a donor DNA template for homology-directed repair. The method enables precise, programmable editing of genomic loci in human and other mammalian cells by directing the Cas9-gRNA ribonucleoprotein complex to specified chromosomal positions via Watson-Crick base pairing between the spacer and the protospacer adjacent to a PAM sequence. Applications include correction of genetic mutations, gene knockouts, and insertion of exogenous sequences.
Search Results
Ranked Prior Art References
7 candidates found across Espacenet + Google Patents — 5 material references
WO 2007/025097 Material
92/100
CRISPR-Based Sequence-Specific DNA Targeting and Cleavage
University of California / Doudna Lab · 2007-03-01
Directly anticipates the core Cas9-gRNA targeting mechanism claimed; establishes in vitro functionality of programmable DNA cleavage via guide RNA — identical concept to the disclosure.
View patent →
US 8,697,359 Material
88/100
CRISPR-Cas Systems and Methods for Altering Expression of Gene Products
The Broad Institute / MIT · 2014-04-15
Highly overlapping — covers eukaryotic CRISPR-Cas9 editing with guide RNA and Cas9; same cell type and editing modality as the disclosure.
View patent →
EP 2 764 103 B1 Material
86/100
RNA-Guided Human Genome Engineering via Cas9
The Trustees of Harvard University · 2012-12-12
Covers sgRNA-guided Cas9 in human cells with multiplex editing — substantial overlap with the claimed method and cell type scope.
View patent →
WO 2013/142578 Material
74/100
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation
The Broad Institute · 2013-09-26
Relevant to delivery and optimization aspects; partially overlaps with the donor DNA template and HDR embodiments mentioned in the disclosure.
View patent →
US 2014/0068797 A1 Material
71/100
Methods of Genome Engineering Using CRISPR-Cas9 with Donor Template for HDR
Sangamo Therapeutics · 2014-03-06
Directly covers the HDR with donor template embodiment recited in the disclosure; may limit the optional donor DNA template claim element.
View patent →
LLM Output
Novelty Report
Structured Novelty Analysis Cached · Run 2026-06-19

Agent jetzt ausprobieren

Dieselben Agents live auf Ihren eigenen Fällen. Prior-Art-Suche und Office-Action-Response — ab $99/Monat, 14 Tage kostenlos testen.

Preise ansehen →

Or email directly: claimforge@polsia.app